Intra-Cellular Therapies, Inc. (ITCI) Stock Overview
Explore Intra-Cellular Therapies, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Intra-Cellular Therapies, Inc. (ITCI)
Key Financials
Key Financials
Market Cap
14B
P/E Ratio
-183.15
EPS (TTM)
$-0.73
ROE
-0.09%
ITCI Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Intra-Cellular Therapies, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ITCI on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $133.77 for the NASDAQ listing.
Key metrics behind Intra-Cellular Therapies, Inc.'s NASDAQ-traded stock include a P/E ratio of -183.15 and a market capitalization of 14B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ITCI on the NASDAQ.